CN106551941A - Progesterone is promoting the effect of ischemic Survival of Random Flap survival - Google Patents
Progesterone is promoting the effect of ischemic Survival of Random Flap survival Download PDFInfo
- Publication number
- CN106551941A CN106551941A CN201610917980.0A CN201610917980A CN106551941A CN 106551941 A CN106551941 A CN 106551941A CN 201610917980 A CN201610917980 A CN 201610917980A CN 106551941 A CN106551941 A CN 106551941A
- Authority
- CN
- China
- Prior art keywords
- survival
- flap
- progesterone
- ischemic
- random
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to progesterone is in the effect for promoting the survival of ischemic Survival of Random Flap.During promoting ischemic Survival of Random Flap to survive by the way of intramuscular injection, using method is daily intramuscular injection dosage 10mg/kg, is within 5～7 days a course for the treatment of.Reached a conclusion by substantial amounts of zoopery, use progesterone ischemic Survival of Random Flap can be promoted well to survive so that the survival surface ratio of flap is significantly improved.
Description
Technical field
The present invention relates to progesterone is in the effect for promoting the survival of ischemic Survival of Random Flap.
Background technology
In recent years, industry, traffic, energy etc. are presented high speed development, extensive wound related to this, tissue defect case
Also increasing and decreasing year by year.This kind of wound after repair more leaves different degrees of deformity and dysfunction, especially hand and face
The wound deformity in portion.Clinically, flexibly and conveniently (Fig. 1) [1] that Survival of Random Flap is used because of which, has become repair tissue and lacks
One of routine operation of damage.But the length-width ratio of Survival of Random Flap suffers from certain restriction, once exceed 1.5-2：1 length
Wide ratio, flap distal end occurs ischemic necrosis.Therefore, how to increase the survival of ischemic Survival of Random Flap, improve flap microcirculation, increase
Fortune is healed, strengthens tolerance of the flap to anoxic, it is ensured that higher survival rate, to improving clinical flap range of application and exploring high
Effect, special prevention and controls have important clinical significance.
Progesterone is a kind of natural progestogen secreted by corpus luteum, in vivo estrogen was excited also known as progesterone
Endometrium have notable Morphology Effects, by maintain gestation it is required.Progesterone（Progesterone）It is clinically used for threatened abortion, practises
Reactivity diagnosis of the amenorrhoeas such as inertia miscarriage or amenorrhoea reason etc., to survival length of flap without report.
The content of the invention
It is an object of the invention to provide a kind of progesterone is in the effect for promoting the survival of ischemic Survival of Random Flap.Promote ischemic with
During meaning survival length of flap by the way of intramuscular injection, using method is daily intramuscular injection dosage 10mg/kg, is within 5～7 days one
The course for the treatment of.
Reached a conclusion by substantial amounts of zoopery, use progesterone can so that the survival surface ratio of flap is significantly improved,
Ischemic Survival of Random Flap can be promoted well to survive.
Description of the drawings
Fig. 1 is ischemic Survival of Random Flap model schematic of the present invention；
Fig. 2 progesterone experimental group and the saline control group comparison diagram of postoperative 7 days；
Fig. 3 progesterone group is schemed with physiological saline group zone line flap HE staining versus.
Specific embodiment
Progesterone can promote ischemic Survival of Random Flap viability to significantly improve.Using method is daily intramuscular injection dosage 10mg/kg,
It is within 5～7 days a course for the treatment of.The evaluation of effect below survived in promotion ischemic Survival of Random Flap for progesterone：
1st, ischemic Survival of Random Flap model is set up
From the male SD rat 40 of health, provided by Wenzhou Medical University's Experimental Animal Center, cleaning grade, SCXK（Zhejiang）
2005-0019, body weight 200-250g, 2-3 monthly ages.Rat is divided into into progesterone experimental group and physiology according to random digits table
Saline control group, 15 per group.Using McFarlane flap preparation methods [1,2] of improvement, 10% chloraldurate lumbar injection
Anesthesia, animal prone position is fixed, and loses hair or feathers, iodophor disinfection, drape, with two interiliac line of rat tailses as the base of a fruit, hits exactly at back
One width 3cm of design, long 9cm rectangles random pattern skin flap, design lines cut skin, and hypodermis, up to deep fascia shallow-layer, retains corium
Lower capillary network, separates hypodermis in deep fascia shallow-layer surface, runs into well-known blood vessel and is ligatured with 4-0 silk threads.Flap
After starting completely, thoroughly stop blooding, silk suture interrupted suture is admired with 4-0 is medical immediately.Gold is smeared around otch after iodophor disinfection mould
Plain ointment, intraperitoneal injection of saline (50 rnl/kg) Hemorrhagic shock, as shown in Figure 1.
Progesterone experimental group：10 mg/kg progesterone lumbar injections, saline control group：Same dose lumbar injection, often
Day 1 time, continuous injection 7 days.Because rat has autotomy phenomenon, to avoid its postoperative wound of later baiting from affecting survival length of flap, it is
Which takes " the neck set " for preventing its autotomy, and single cage is fed.To reduce the error that operation technique brings, all operations are complete by 1 people
Into.
2nd, observation index：
The detection of 2.1 Flap survival ratios
The detection of Flap survival ratio：Postoperative 7th day, each group rat under narcosis with cellophane paper accurately measure flap into
Living and necrosis area, and be cut into and survive or dead two parts, respectively with electronic scale weighing.Survival length of flap face is calculated as follows
Product ratio：Flap survival ratio=Flap survival glass paper weight/flap total surface area glass paper weight × 100%).Skin
Lobe necrosis standard：Flap is black, and tissue recoil, poor flexibility, quality are hard, cutting tissue not bleeding.Pathological manifestations are group
Knit disintegration, hypochromatosis, inflammatory cell extensively to infiltrate, have focal bleeding.After 7 days, the survival surface ratio of experimental group flap is（
81.62 ±4.56）%, control group Skin Flaps area ratio is（49.78± 3.34）%, compares the survival surface of two groups of flaps
Than difference is statistically significant（P<0.01）.
Can see referring to Fig. 2, postoperative 7 days, progesterone group zone line flap color is light red, and surface is without scab hull shape into bullet
Property preferably, remote area is black, shows there is scab shell, poor flexibility, and original position sees when starting flap that flap bleeding is enlivened, amount of bleeding
It is many, without hematocele under sarcolemma, hydrops, rich blood vessel.Physiological saline group flap zone line and remote area color black, surface
There is scab hull shape into elastic extreme difference, original position start flap and see that flap bleeding is less, and rheuminess thing is more under sarcolemma, and blood vessel is relative
Relatively dredge.
2.2 histology
Flap takes flap sample in postoperative 7 days, and skin flap tissues are soaked in 10% neutral formalin liquid fixed, FFPE,
Make 4 microns of slabs, HE dyeing, light Microscopic observation granulation tissue thickness degree, tissue edema, necrosis, inflammatory cell infiltration
Situations such as.5 visuals field counting neutrophil numbers are arbitrarily chosen under 10 × 10 times of light microscopics to average.Neutrophil leucocyte meter
Number, progesterone group area (30.10 ± 6.54) in flap is individual/mm2.Control group area (44.80 ± 8.68) in flap is individual/
mm2, Liang Zuzhong areas neutrophil leucocyte density ratio is compared with difference is statistically significant（P ＜ 0.05）, referring to Fig. 3.By in Fig. 3
With physiological saline group zone line flap HE dyeing observations, progesterone group can see that progesterone group is shown in fibroblast proliferation, granulation
Tissue is relatively thin, and tissue edema is less, and inflammatory cell infiltration is few.Physiological saline group fibroblast proliferation is less, and tissue edema is bright
Aobvious, inflammatory cell infiltration is serious.
The detection of 2.3 SOD, MDA expression
Postoperative 7 days, in flap, area center position cut 0.5 cm × 0.5 cm holostrome tissues, removes sarcolemma layer, claims quality,
Dilution, makes 10% tissue homogenate of volume fraction in ice-water bath. according to SOD, MDA detection kit specification, both detections
Content.
Superoxide dismutase in progesterone group every milligram of albumen of skin flap tissues（SOD）Content is (61.40 ± 5.60) U, bright
Show higher than physiological saline group (29.95 ± 7.12) U, difference is statistically significant（P< 0.01）；MDA in every milligram of albumen
（MDA）It is (62.32 ± 13.18) nmol that content experimental group is (16.25 ± 7.54) nmol, control group, and difference has statistics
Learn meaning (P<0.01).
2.4 immunohistochemical observation
Detection VEGF（VEGF）In expression and the distribution situation of experimental group and control group.Selective staining is uniform
Region, is observed under 40 × 10 times of light microscopics, and every slice, thin piece takes five visuals field and shoots preservation, in shooting process, arranges white
The parameters such as balance, aperture time are consistent.The picture for preserving is imported into Image-Pro Plus v6.0 softwares, selection needs analysis
Index " accumulation absorbance IA value ", read IA numerical value measure, as evaluate VEGF expression index.Two groups
VEGF Immunohistochemical Expressions, by calculating cumulative absorbance A values（IA）, experimental group VEGF expression 3479 ± 167 is obtained,
Control group VEGF expressions 1923 ± 105, two groups of comparing differences are statistically significant（P ＜ 0.01）.
Claims (2)
1. progesterone is promoting the effect of ischemic Survival of Random Flap survival.
2. progesterone according to claim 1 is promoting the effect of ischemic Survival of Random Flap survival, it is characterised in that：Using method
For daily intramuscular injection dosage 10mg/kg progesterone, it is within 5～7 days a course for the treatment of.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610917980.0A CN106551941A (en) | 2016-10-21 | 2016-10-21 | Progesterone is promoting the effect of ischemic Survival of Random Flap survival |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610917980.0A CN106551941A (en) | 2016-10-21 | 2016-10-21 | Progesterone is promoting the effect of ischemic Survival of Random Flap survival |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106551941A true CN106551941A (en) | 2017-04-05 |
Family
ID=58443962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610917980.0A Pending CN106551941A (en) | 2016-10-21 | 2016-10-21 | Progesterone is promoting the effect of ischemic Survival of Random Flap survival |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106551941A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107456570A (en) * | 2017-07-31 | 2017-12-12 | 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 | Effect of the oxytocins in the survival of ischemic ultra long random flap is promoted |
| CN108159405A (en) * | 2018-01-31 | 2018-06-15 | 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 | Batroxobin is in the effect for promoting the survival of ischemic ultra long random flap |
| CN110935015A (en) * | 2019-07-16 | 2020-03-31 | 温州医科大学附属第二医院温州医科大学附属育英儿童医院 | Function of ulirelilin in promoting survival of ischemic overlong random skin flap |
-
2016
- 2016-10-21 CN CN201610917980.0A patent/CN106551941A/en active Pending
Non-Patent Citations (1)
| Title |
|---|
| O. ATA UYSAL: "The effect of progesterone hormone on the viability of flaps", 《EUR J PLAST SURG》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107456570A (en) * | 2017-07-31 | 2017-12-12 | 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 | Effect of the oxytocins in the survival of ischemic ultra long random flap is promoted |
| CN108159405A (en) * | 2018-01-31 | 2018-06-15 | 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 | Batroxobin is in the effect for promoting the survival of ischemic ultra long random flap |
| CN110935015A (en) * | 2019-07-16 | 2020-03-31 | 温州医科大学附属第二医院温州医科大学附属育英儿童医院 | Function of ulirelilin in promoting survival of ischemic overlong random skin flap |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106551941A (en) | Progesterone is promoting the effect of ischemic Survival of Random Flap survival | |
| Klemperer | Myoblastoma of the striated muscle | |
| CN107456570A (en) | Effect of the oxytocins in the survival of ischemic ultra long random flap is promoted | |
| DE60222168T2 (en) | ANTAGONISTS OF PROSTAGLANDINE EP2 AND / OR EP4 RECEPTORS FOR THE TREATMENT OF MENORRHAGIA | |
| CN105031708B (en) | A kind of wound rapid hemostasis powder and preparation method thereof | |
| CN108159065B (en) | Application of morroniside in promoting survival of ischemic overlong random skin flap | |
| CN111888349B (en) | Action of nimbin in preparing medicine for promoting survival of ischemic superlong random skin flap | |
| CN100525798C (en) | Medicine for treating women's inflammation and its preparing method | |
| CN107233341A (en) | Tirofiban is promoting the effect of ischemic Survival of Random Flap survival | |
| CN110279847A (en) | Application of the FGF21 in the drug that preparation promotes ultra long random flap survival | |
| MORI | Histology and innervation of prostata and pars pelvina urethrae in cat | |
| CN108309993B (en) | Application of curculigoside in promoting survival of ischemic overlength random flap | |
| Mehra et al. | The relationship between endometrial mast cell count and bleeding in women following insertion of an intrauterine device | |
| CN114533748B (en) | Application of pulsatilla chinensis saponin B4 in preparation of medicines for treating or preventing hysteromyoma | |
| CN109620835A (en) | Asiaticosid is in the effect for promoting the survival of ischemic ultra long random flap | |
| Noegroho et al. | THE COMBINE CREAM MIXTURE OF NIGELLA SATIVA AND OLEA EUROPAEA FASTEN THE BURN HEALING PROCESS WITH MINIMAL SCAR | |
| CN105963338B (en) | Prevent and treat the herbal composite of cervical erosion | |
| CN114558024A (en) | Application of paeoniflorin in preparation of medicine for promoting survival of ischemic overlong random skin flap | |
| CN110935015A (en) | Function of ulirelilin in promoting survival of ischemic overlong random skin flap | |
| CN104840473A (en) | Application of tanshinone II A in preparing medicine for curing tendon adhesion | |
| Wang et al. | The Yiqi Huashi Tongluo formula combined with a nano-shenkangning preparation improves inflammatory fibrosis in rats with chronic renal failure by regulating the NF-κB signaling pathway | |
| CN102085361B (en) | Application of medicament containing hirudin and hementerin | |
| Hanson et al. | Myoblastoma of the vulva | |
| CN111437305A (en) | Traditional Chinese medicine composition for treating haemorrhoids | |
| CN104906210A (en) | Traditional Chinese medicine externally applied lotion for treating colpitis mycotica and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170405 |